314 related articles for article (PubMed ID: 27246234)
1. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
Seroy JT; Grim SA; Reid GE; Wellington T; Clark NM
J Antimicrob Chemother; 2016 Sep; 71(9):2563-8. PubMed ID: 27246234
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes.
Giancola SE; Mahoney MV; Hogan MD; Raux BR; McCoy C; Hirsch EB
Chemotherapy; 2017; 62(2):100-104. PubMed ID: 27788499
[TBL] [Abstract][Full Text] [Related]
3. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.
Matthews PC; Barrett LK; Warren S; Stoesser N; Snelling M; Scarborough M; Jones N
BMC Infect Dis; 2016 Oct; 16(1):556. PubMed ID: 27729016
[TBL] [Abstract][Full Text] [Related]
4. Treatment of recurrent complicated urinary tract infections in children with vesicoureteral reflux.
Wu TH; Huang FL; Fu LS; Chou CM; Chien YL; Huang CM; Lin CF; Chen PY
J Microbiol Immunol Infect; 2016 Oct; 49(5):717-722. PubMed ID: 25442872
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
6. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
Neuner EA; Sekeres J; Hall GS; van Duin D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5744-8. PubMed ID: 22926565
[TBL] [Abstract][Full Text] [Related]
7. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
8. Fosfomycin: Resurgence of an old companion.
Sastry S; Doi Y
J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
Fedrigo NH; Mazucheli J; Albiero J; Shinohara DR; Lodi FG; Machado ACDS; Sy SKB; Tognim MCB
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607025
[TBL] [Abstract][Full Text] [Related]
11. Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature.
Babiker A; Clarke L; Doi Y; Shields RK
Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114856. PubMed ID: 31307867
[TBL] [Abstract][Full Text] [Related]
12. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Wilson DT; May DB
Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
[TBL] [Abstract][Full Text] [Related]
13. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.
Patwardhan V; Singh S
Int Urol Nephrol; 2017 Sep; 49(9):1637-1643. PubMed ID: 28616818
[TBL] [Abstract][Full Text] [Related]
14. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
[TBL] [Abstract][Full Text] [Related]
15. Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.
Sastry S; Clarke LG; Alrowais H; Querry AM; Shutt KA; Doi Y
Antimicrob Agents Chemother; 2015 Dec; 59(12):7355-61. PubMed ID: 26369978
[TBL] [Abstract][Full Text] [Related]
16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). II. Background of patients].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
Jpn J Antibiot; 1995 Sep; 48(9):1161-73. PubMed ID: 7474334
[TBL] [Abstract][Full Text] [Related]
17. Fosfomycin: Mechanism and Resistance.
Silver LL
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28062557
[TBL] [Abstract][Full Text] [Related]
18. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.
Abbott IJ; Meletiadis J; Belghanch I; Wijma RA; Kanioura L; Roberts JA; Peleg AY; Mouton JW
J Antimicrob Chemother; 2018 Mar; 73(3):709-719. PubMed ID: 29253153
[TBL] [Abstract][Full Text] [Related]
19. The revival of fosfomycin.
Michalopoulos AS; Livaditis IG; Gougoutas V
Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
[TBL] [Abstract][Full Text] [Related]
20. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study.
Rudenko N; Dorofeyev A
Arzneimittelforschung; 2005; 55(7):420-7. PubMed ID: 16080282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
